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Parkinson’s disease (PD) is a neurodegenerative disorder that is characterized by
loss of midbrain dopaminergic (mDA) neurons in the substantia nigra (SN). Microglia-
mediated neuroinflammation has been described as a common hallmark of PD and
is believed to further trigger the progression of neurodegenerative events. Injections
of 6-hydroxydopamine (6-OHDA) are widely used to induce degeneration of mDA
neurons in rodents as an attempt to mimic PD and to study neurodegeneration,
neuroinflammation as well as potential therapeutic approaches. In the present study, we
addressed microglia and astroglia reactivity in the SN and the caudatoputamen (CPu)
after 6-OHDA injections into the medial forebrain bundle (MFB), and further analyzed
the temporal and spatial expression patterns of pro-inflammatory and anti-inflammatory
markers in this mouse model of PD. We provide evidence that activated microglia as well
as neurons in the lesioned SN and CPu express Transforming growth factor β1 (Tgfβ1),
which overlaps with the downregulation of pro-inflammatory markers Tnfα, and iNos,
and upregulation of anti-inflammatory markers Ym1 and Arg1. Taken together, the data
presented in this study suggest an important role for Tgfβ1 as a lesion-associated factor
that might be involved in regulating microglia activation states in the 6-OHDA mouse
model of PD in order to prevent degeneration of uninjured neurons by microglia-mediated
release of neurotoxic factors such as Tnfα and nitric oxide (NO).
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INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disorder that is characterized by loss of
midbrain dopaminergic (mDA) neurons in the substantia nigra (SN) and the subsequent
loss of axonal projections to the caudatoputamen (CPu) resulting in decreased dopamine
levels (Jellinger, 2001). Although the causes that trigger disease onset remain elusive in the
majority of cases and environmental factors are discussed (Goldman, 2014), neuroinflammation
mediated by microglia has been described as a common hallmark of PD and is believed to fuel
the progression of neurodegenerative events by releasing neurotoxic factors such as Tnfα and
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nitric oxide (NO; Block et al., 2007; Hirsch and Hunot, 2009).
Microglia—the resident immune cells of the central nervous
system (CNS)—are involved in a plethora of neurodegenerative
pathologies (Prinz and Priller, 2014) and interestingly, show
a higher density in the SN and CPu as compared to other
brain areas (Lawson et al., 1990; Sharaf et al., 2013). In
human PD cases, microglia reactivity has been extensively
described (McGeer and McGeer, 2008). Moreover, due to their
unique origin (Prinz and Priller, 2014), microglia undergo
ageing and are believed to become senescent, a phenomenon
which is likely to impair their normal functions (Streit,
2006). Interestingly, aged microglia show a propensity towards
inflammatory reaction states (Lee et al., 2013) indicating that
ageing might generate an environment that could be harmful
for mDA neurons and potentially explain the age-dependent
onset of PD.
Experimental approaches to develop sufficient animal models
for PD, which reproduce features of the human disease, have
not yet resulted in a successful model. Thus, toxin-based animal
models using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) and 6-hydroxydopamine (6-OHDA) are widely
used to mimic the PD situation in rodents and to study
neurodegeneration, neuroinflammation as well as potential
therapeutic approaches (Schober, 2004). Injection of 6-OHDA
has been shown to result in a rapid decrease in tyrosine
hydroxylase (TH)+ fiber densities in the CPu and a delayed
apoptotic cell death of TH+ dopaminergic neurons in the
midbrain which follows several days after initial injection
of the toxin (Martí et al., 2002; Stott and Barker, 2014).
Notably, activation of microglia occurs rapid after injection
of 6-OHDA and has been demonstrated to precede the
degeneration of mDA neurons (Marinova-Mutafchieva et al.,
2009; Walsh et al., 2011). 6-OHDA-intoxicated neurons die
by apoptotic cell death (Martí et al., 2002), which normally
would not result in an inflammatory response. However,
either 6-OHDA-induced neuronal impairment, or released
inflammatory factors result in microglia activation prior to
neuron death. Moreover, direct physical interactions and
cell-to-cell communications between microglia and neurons
are essential during 6-OHDA-induced neurodegeneration and
neuroinflammation (Virgone-Carlotta et al., 2013). Due to
the fact that microglia-mediated neuroinflammation is able to
increase and accelerate progression of mDA neurodegeneration
(Block et al., 2007), the extent and duration of microglia
activation has to be tightly regulated in order to prevent
threatening of healthy uninjured neurons. One of the most
potent endogenous factors regulating microglia activation is
Transforming growth factor β1 (Tgfβ1), which has been shown
to be essential for microglia homeostasis in vivo (Butovsky
et al., 2014) and in vitro (Spittau et al., 2013). Moreover,
Tgfβ1 sufficiently blocks microglia activation induced by
LPS (Kim et al., 2004) and IFNγ (Herrera-Molina et al.,
2012; Zhou et al., 2015) and is further important for the
adoption of a microglia alternative activation phenotype,
which is triggered by interleukin 4 (IL4) and is believed
to promote tissue repair and neuroprotection (Zhou et al.,
2012).
In the present study, we describe microglia and astroglia
reactivity in the SN and CPu after 6-OHDA injection into the
medial forebrain bundle (MFB), and further demonstrate the
temporal and spatial expression patterns of pro-inflammatory
and anti-inflammatory markers in this mouse model of PD.
Finally, we provide evidence that activated microglia as well
as neurons in the lesioned SN and CPu express Tgfβ1, which
precedes the downregulation of pro-inflammatory markers.
Together, our data suggest an important role for Tgfβ1 as
a lesion-associated factor that might regulate expression of
inflammatory markers in the 6-OHDAmodel of PD.
MATERIALS AND METHODS
Animals
Male C57BL/6-mice weighting about 22 g at the beginning
of the experiments were housed at 22 ± 2◦C under a 12 h
light/dark cycle with free access to food and water. All animal-
related procedures were conducted in accordance with the
local ethical guidelines and have been approved by the animal
experimentation committee of the University of Rostock.
Generation of Hemiparkinsonian Mice
Mice (n = 42) were deeply anaesthetized by an intraperitoneal
injection of Ketamin (75 mg/kg) and Rompun (5.8 mg/kg)
and mounted in a mouse adaptor (Stoelting Co) fixed in a
rat stereotaxic apparatus (Kopf, Tujunga, CA, USA). The skull
was opened with a dental thrill and animals were unilaterally
lesioned by an injection of 6-hydroxydopamine (6-OHDA-
HCl, Sigma) into the right MFB via a 26 ga Hamilton syringe
[5 µg 6-OHDA/2 µl, solved in 0.9% saline containing 0.02%
ascorbic acid (Merck), coordinates referring to bregma: AP
−1.2, ML −1.1, V −5 (Dura)] (Paxinos and Franklin, 2011).
The solution was injected over a time period of 4 min, after
further 3 min the syringe was pulled of slowly and the skin was
sutured. Then the animals received supplementary baby food
(cereals and fruit mash) and chocolate to prevent heavy weight
loss.
Tissue Processing and
Immunohistochemistry
Mice were injected with an overdose of pentobarbital (60 mg/kg)
and transcardially perfused with ice cold 0.9% sodium chloride
(10 ml), followed by 50 ml of 3.7% PFA. Brains were immediately
removed from the skull, postfixed overnight, and transferred
into 0.1 M PBS containing 20% sucrose (overnight, 4◦C). The
cryoprotected brains were frozen in isopentane (−50◦C) and
stored at −80◦C. Brains were cut with a cryostat at 30 µm and
serial sections were collected free-floating in a cryoprotective
solution and stored at −20◦C until further processing. For
immunohistochemical analysis of neuronal loss, microgliosis
and astrogliosis, sections from SN and caudatoputamen (CPu)
were washed three times with PBS, blocked with 10% normal
goat serum (Vector Laboratories) and 0.1% Triton-X/100 for
1 h at room temperature (RT), and then incubated with anti-
TH (1:500, polyclonal, Millipore), anti-Iba1 (1:500, polyclonal,
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Wako), anti-Gfap (1:800, monoclonal, Millipore), anti-Map2
(1:500, polyclonal, Abcam) primary antibodies overnight at
4◦C. This was followed by incubation with goat anti-mouse
or goat anti-rabbit fluorescence-coupled secondary antibodies
(1:200, Cell Signaling Technologies) for 1 h at RT. The
sections were washed three times with PBS for 3 min
each and nuclei were counterstained using 4′,6-diamidino-2-
phenylindole (DAPI, Roche). After final washing, sections were
placed on objective slides and mounted with Fluoromount
medium (SouthernBiotech). Fluorescence images were captured
using the Leica AF6000 imaging system (LEICA, Wetzlar,
Germany) and the Zeiss AxioImager M2 (Zeiss, Göttingen,
Germany).
RNA Isolation and Reverse Transcription
Mice were sacrificed by cervical dislocation at the designated
timepoints and the SN and CPu from the lesioned and the
unlesioned hemispheres were dissected and transferred to RNA
later (Ambion). The tissues were then homogenized in peqGOLD
TriFast (Peqlab) using the Precellys 24 homogenizer (Peqlab).
RNA was extracted according to the manufacturer’s instructions.
Quality and concentration of isolated RNAwas determined using
a NanoDrop spectrophotometer (Thermo Scientific). 1 µg RNA
was reverse transcribed to cDNA using the GeneAmp RNA PCR
Core Kit (Applied Biosystems) and random hexamer primers
according to manufacturer’s instructions.
Quantitative RT-PCR
Expression of inflammatory and anti-inflammatory factors
was detected using cDNAs from control and lesioned SN
and CPu isolated at 1 day, 2 days, 6 days, 8 days and 14 days
after 6-OHDA injections into the MFB. Quantitative RT-
PCR analysis was performed using the MyiQTM (BIO-RAD,
München, Germany) and the Quantitect SYBR Green PCR
Kit (Applied Biosystems, Darmstadt, Germany) with 1 µl of
cDNA template in a 25 µl reaction mixture. Results were
analyzed using the Bio-Rad iQ5 Opitcal System Software and
the comparative CT method. Data throughout the study are
expressed as 2−∆∆CT for the experimental gene of interest
normalized to the housekeeping gene Gapdh and presented
as fold change relative to the unlesioned control side of each
individual mouse. The primers used throughout this study are:
iNosfor 5′-TTGACGCTCGGAACTGTAGCAC-3′, iNosrev 5′-
CGACCTGATGTTGCCATTGTTG-3′ [NM_010927], Tnfαfor
5′-TCTACTGAACTTCGGGGTGATCG-3′, Tnfαrev 5′-TGAT
CTGAGTGTGAGGGTCTGGG-3′ [NM_013693.3], Ym1for
5′-AGACTTGCGTGACTATGAAGCATTG-3′, Ym1rev 5′-GC
AGGTCCAAACTTACATCCTC-3′ [NM_009892.2], Arg1for 5′-
TCATGGAAGTGAACCCAACTCTTG-3′, Arg1rev 5′-TCAGT
CCCTGGCTTATGGTTACC-3′ [NM_007482.3], Tgfβ1for
5′-TAATGGTGGACCGCAACAACG-3′, Tgfβ1rev 5′-TCCCGA
ATGTCTGACGTATTGAAG-3′ [NM_011577.1], ActivinAfor
5′-TTCCAAGGAAGGCAGTGACCTG-3′, ActivinArev 5′-GC
TGCTGAAATAGACGGATGGTG-3′ [NM_008380], Mfge8for
5′-GGGCATCCACTGTGAAACCGAGAC-3′, Mfge8rev 5′-GC
AATGGTGCCCCCTTCCAT-3′ [NM_008594.2], Gapdhfor
5′-GGCATTGCTCTCAATGACAA-3′, Gapdhrev 5′-ATGTAG
GCCATGAGGTCCAC-3′ [NM_008084].
Tnfα and Tgfβ1 Immunohistochemistry
For the detection of Tnfα and Tgfβ1 2 days after lesion
with 6-OHDA, sections from SN and CPu were washed
with PBS and blocked with PBS containing 10% normal
goat serum and 0.1% TritonX-100 (Roche) for 1 h at RT.
Afterwards, sections were incubated with primary antibodies
anti-Tnfα (sc-52746, 1:100, Santa Cruz), anti-Tgfβ1 (MAB240,
R&D System, 1:50, Wiesbaden-Nordenstedt) and anti-Iba1
(1:500, Wako Chemicals) at 4◦C overnight, followed by an
incubation with the corresponding Cy3-conjugated secondary
antibodies (goat anti-mouse Cy3 1:100, goat anti-rabbit Cy3
1:200, Cell Signaling Technologies) for 1 h at RT. Nuclei
were counterstained using 4′,6-diamidino-2-phenylindole
(DAPI, Roche). Fluorescence images were captured using the
ZEISS AxioImager M2 imaging system (ZEISS, Göttingen,
Germany).
Quantifications of Iba1+ and Gfap+ Cells
after 6-OHDA Lesion
Coronal sections from SN and CPu of 6-OHDA lesioned brains
were stained with antbodies against Iba1 and Gfap (as described
under ‘‘Tissue processing and immunohistochemistry’’ Section)
and mounted onto objective slides. Immunofluorescent images
were taken with a ZEISS AxioImager M2 imaging system (ZEISS,
Göttingen, Germany) and were used for counting the numbers
of Iba1+ and Gfap+ cells using ImageJ software (National
Institutes of Health). Three animals per time-point were used,
and cells in SN and CPu on control and lesioned side were
counted in a 0.5 mm2 counting grid. Activated Iba1+ microglia
were determined based on amoeboid morphology, thickened
processes and an increased staining intensity. Numbers of cells
were recalculated and presented as cells/mm2.
Statistics
Data are expressed as means ± SEM. Statistical significances
between multiple groups were compared using a one-way
ANOVA followed by a Bonferroni’s multiple comparison
test. Two-group analysis was performed using a Student’s
t-test. Values of p less than or equal to 0.05 were considered
as statistically significant. All statistical analyses were
performed using the GraphPad Prism5 software (GraphPad
Software Inc).
RESULTS
6-OHDA Injections Induce Robust Striatal
Denervation and Loss of TH-positive
Dopaminergic Midbrain Neurons
Male C57BL/6 mice were unilaterally lesioned by an injection of
5 µg 6-OHDA into the right MFB. A shown in Figures 1A–C,
analysis of the nigrostriatal system 2 days after injection of
6-OHDA showed a rapid loss of TH-immunoreactivity in the
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FIGURE 1 | 6-OHDA injections into the MFB induce robust loss of mDA neurons and denervation in the CPu on the lesioned side. Coronal brain sections
after immunohistochemistry for TH from CPu and ventral midbrains containing SN and VTA are shown 2 days (A–C), 6 days (D–F), 8 days (G–I) and 14 days (J–L)
after 6-OHDA injections. Whereas loss of TH+ fibers in the CPu occurs from 2 days onwards, substantial decrease in numbers of TH+ mDA neurons was evident
after 6 days. Representative images from three independent experiments are shown. Scale bars indicate 300 µm (B,E,H,K) and 1 mm for all CPu images.
Quantification of SN and VTA TH+ mDA neurons revealed significant decreases in SN neurons at all time-points analyzed. However, decrease of VTA neurons was
delayed and reached significant differences at 8 days and 14 days (M). Data are given as percentages from unlesioned sides ± SEM from three animals.
CPu on the lesioned side (Figure 1C), with residual TH+ fiber
clumps in basal parts of the CPu. The staining intensities of
TH+ neurons in the SN were slightly decreased, and substantial
neuron losses could be detected at 2 days after injection
(Figures 1B,M). At 6 days (Figures 1D–F), 8 days (Figures 1G–I)
and 14 days (Figures 1J–L) after injection of 6-OHDA, no
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TH+ fibers could be detected on the lesioned sides. Moreover,
TH+ SN neuron numbers on lesioned sides gradually decreased
from 2 days to 6 days (Figures 1E,M) and almost no TH+ SN
neurons were present at 8 days (Figures 1H,M) and 14 days
(Figures 1K,M) after 6-OHDA injection. Further, numbers of
TH+ neurons in the ventral tegmental area (VTA) started
to decrease from 8 days (Figures 1D,E,F,M) after 6-OHDA
injections. At 14 days after injection, only some TH+ VTA
neurons were detectable (Figures 1K,M). Together, these data
clearly demonstrate that an injection of 6-OHDA into the MFB
induced a rapid and robust decrease of striatal target innervation
and loss of TH+ midbrain neurons.
Microglia and Astroglia Reactions in the
6-OHDA-Lesioned SN
After establishment of the temporal pattern of midbrain TH+
neuron loss in male C57BL/6 mice induced by 6-OHDA, the
time course of microglia and astroglia reactivity in the SN
was addressed. As depicted in Figure 2, microglia on control
sides showed ramified morphologies with fine processes as
demonstrated using Iba1-immunohistochemistry (Figure 2A).
However, 2 days after 6-OHDA injections microglia in the
lesioned SN displayed reduced branching behavior, increased
cell size and a stronger Iba1-immunoreactivity (Figure 2B).
These microglia morphology changes have been described
as reactive changes in several CNS disease models (Block
et al., 2007), and are used as a crude readout for microglia
activation. After 6 days, microglia morphologies started to
normalize. However, even at 8 days and 14 days (Figure 2B)
microglia morphologies on lesioned sides substantially differed
from control sides, suggesting that microglia in the SN are
rapidly and strongly reacting upon 6-OHDA lesions reaching
a maximum after 2 days but seem to stay in a reactive
state at all time-points analyzed. Quantifications of total
microglia numbers revealed slight increases after 2 days, 6 days,
8 days and 14 days (Figure 2E). Significant increases were
observed at 6 days (p = 0.0216) and 8 days (p = 0.0334).
Significant increases in activated microglia numbers in the SN
on lesioned sides were observed at all time-points analyzed
(Figure 2F).
Using Gfap-immunohistochemistry, the reactivity of
astrocytes was analyzed in midbrains on lesioned sides at
different time-points. As shown in Figure 2C, Gfap+ astrocytes
could be detected in the SN on control sides at all time-points
analyzed. On lesioned sides, astrocytic staining intensities as well
as total numbers of Gfap+ cells were increased at 2 days, 6 days,
8 days and 14 days (Figure 2D) after injection of 6-OHDA to the
MFB. Quantifications of Gfap+ astrocytes (Figure 2G) revealed
significantly increased numbers on lesioned sides after 2 days
(p = 0.0149), 6 days (p = 0.038) and 14 days (p = 0.02).
Microglia and Astroglia Reactions in the
6-OHDA-Lesioned CPu
Microglia and astroglia reactions were further analyzed in
the 6-OHDA-lesioned CPu. Figure 3A displays microglia on
control sides showing normal ramified morphologies. Two days
after 6-OHDA injection, a strong microglia reactivity on the
lesioned side was observed (Figure 3B). Interestingly, from
6 days onwards, ramified microglia with fine processes could be
detected at 8 days and 14 days (Figure 3B). Quantifications of
total microglia (Figure 3E) and activated microglia (Figure 3F)
revealed slight increases in total numbers on lesioned sides at all
time-points analyzed. Numbers of activated microglia reached a
maximum on lesioned sides after 2 days and were only slightly
different as compared to control sides at 6 days, 8 days and
14 days (Figure 3F), indicating that microglia reactivity in the
CPu is rapidly downregulated after 2 days.
Analysis of Gfap+ astrocytes revealed virtually no Gfap+
cells in the CPu on control sides at all time-points analyzed
(Figure 3C). After injection of 6-OHDA, astrocyte reactivity was
not observed 2 days after lesion. However, at 6 days, 8 days
and 14 days after 6-OHDA injection, a strong astrocytic Gfap
reactivity could be detected in the lesioned CPu (Figures 3D,G).
These data demonstrate thatmicroglia reactivity in the 6-OHDA-
lesioned CPu precedes astrocyte activation but is rapidly
downregulated, whereas astrocyte reactivity starts from 6 days
and remains activated until 14 days after lesion.
Temporal Expression Patterns of
Inflammatory Markers in the
6-OHDA-Lesioned Nigrostriatal System
Based on the immunohistochemical observations of microglia
and astroglia reactions after 6-OHDA injections, mRNA was
isolated from the SN and CPu at different time-points after
injection of 6-OHDA into the MFB to detect the expression
of inflammatory markers. The expression levels of the M1
activation markers Tnfα and iNos, the M2 activation markers
Ym1 and Arg1, as well as of Tgfβ1 and ActivinA as anti-
inflammatory factors were analyzed. As shown in Figure 4A,
Tnfα was significantly upregulated in the CPu of lesioned mice
1 day (p = 0.0313) and 2 days (p = 0.0232) after injection.
Although a slight upregulation of Tnfα was also detectable in
the SN at all time-points analyzed, these increases did not reach
statistical significances. Analysis of iNos expression revealed that
6-OHDA lesion induced an expression of iNos in the SN 1 day
and 2 days post lesion, whereas the expression in the CPu
was not increased at these time-points. From 6 days onward,
a slight increase in iNos expression was observed in the CPu,
however, not reaching any statistical significance (Figure 4B).
Ym1 and Arg1 have been recently described as markers for
alternative microglia activation (Zhou et al., 2012), and thus were
analyzed after injections of 6-OHDA into the MFB. Ym1 was
highly upregulated in the lesioned CPu 1 day after injection.
After 2 days, increased Ym1 expression was observed in the
lesioned SN as well as in the lesioned CPu (p = 0.0065). At
6 days and 8 days post lesion, there were no changes in Ym1
expression neither in the SN nor in the CPu. Interestingly, a
significant upregulation of Ym1 (p = 0.0282) was evident in the
CPu after 14 days (Figure 4C). A similar, yet lessened regulation
could further be observed for Arg1 after lesion with 6-OHDA.
As shown in Figure 4D, a significant upregulation of Arg1 was
detectable in the SN (p = 0.0437) and in the CPu (p = 0.0424)
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FIGURE 2 | Microglia and astroglia reactivity in the SN after 6-OHDA injections. On the control side microglia showing ramified morphologies could be
detected by Iba1-immunohistochemistry at all time-points analyzed (A). Two days after 6-OHDA injections, a strong microglia reactivity was observed on the lesioned
side. After 6 days, microglia start to adopt a ramified morphology indicating that microglia reactivity is rapidly inhibited (B). Immunohistochemistry for Gfap
demonstrated the presence of Gfap+ astrocytes in the SN on the control side at all time-points analyzed (C). However, strong increases in Gfap-immunoreactivity
and numbers of Gfap+ astrocytes were observed starting from 6 days after injection of 6-OHDA and persisting until 14 days (D). Scale bars indicate 75 µm.
Quantifications of total microglia (E), activated microglia (F) and Gfap+ astrocytes (G) in the SN on control and lesioned sides. Data are given as numbers/mm2
(mean ± SEM) from three animals per time-point. p-values derived from student’s t-test are ∗p < 0.05 and ∗∗p < 0.01.
1 day after lesion with 6-OHDA. From 2 days to 8 days after
lesion, no significant changes in Arg1 expression could be
demonstrated, although increased expression was observed in the
SN at 2 days and the CPu at 6 days. Noteworthy, similar to Ym1,
the expression of Arg1 was significantly increased (p = 0.0211)
in the lesioned CPu after 14 days (Figure 4D). Furthermore,
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FIGURE 3 | Microglia and astroglia reactivity in the CPu after 6-OHDA injections. Microglia showing ramified morphologies could be detected after
Iba1-immunohistochemistry in the unlesioned CPu at all time-points analyzed (A). Two days after 6-OHDA injections a strong microglia reactivity was observed in the
lesioned CPu, which was not longer visible at 6 days, 8 days and 14 days after injection of 6-OHDA (B). Immunohistochemistry for Gfap showed that virtually no
Gfap+ astrocytes were present in the CPu on the control side at all time-points analyzed (C). Comparable to the observations in the lesioned SN, strong increases in
Gfap-immunoreactivity and numbers of Gfap+ astrocytes in the CPu were observed starting from 6 days after injection of 6-OHDA and again, persisting until
14 days (D). Scale bars indicate 75 µm. Quantifications of total microglia (E), activated microglia (F) and Gfap+ astrocytes (G) in the CPu on control and lesioned
sides. Data are given as numbers/mm2 (mean ± SEM) from three animals per time-point. p-values derived from student’s t-test are ∗p < 0.05 and ∗∗p < 0.01.
the expression of Tgfβ1 and ActivinA as anti-inflammatory
markers was also analyzed. Increases in Tgfβ1 expression were
observed after 1 day in the lesioned CPu reaching a maximum
after 2 days (p = 0.0283). At later time-points, a tendency for
increased Tgfβ1 expression in SN and CPu could be detected,
however, in the SN only after 8 days a significant increase
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FIGURE 4 | Expression of inflammatory markers in SN and CPu after injection of 6-OHDA. The expression levels of the M1 activation markers Tnfα (A) and
iNos (B), the M2 activation markers Ym1 (C) and Arg1 (D) as well as TGFβ1 (E) and ActivinA (F) as anti-inflammatory factors as well as Mfge8 expression (G) as a
TGFβ1-regulated gene have been analyzed and are displayed. Data are given as fold changes (mean ± SEM) calculated from expression levels on unlesioned control
sides from at least three different animals. p-values derived from student’s t-test are ∗p < 0.05 and ∗∗p < 0.01. A summary of the temporal expression patterns of
different markers is given (H).
in Tgfβ1 expression (p = 0.0074) was noticed (Figure 4E).
Analysis of ActivinA expression revealed a similar pattern as
observed for Tgfβ1. Especially in the lesioned CPu, a strong
increase in ActivinA expression was detected after 2 days, 6 days
(p = 0.0251) and 8 days, whereas the lesioned SN showed no
significant changes in ActivinA expression at all time-points
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analyzed (Figure 4F). Finally, the expression of Mfge8 as a
Tgfβ1-regulated gene that is involved in uptake of apoptotic
cells was further analyzed. As shown in Figure 4G, Mfge8 was
upregulated in the SN (p = 0.0742) and the CPu (p = 0.0652)
after 2 days, however, without reaching statistically significant
differences. A summary of the temporal expression patterns of
inflammatory and anti-inflammatory markers in the CPu, which
has shown a more prominent expression of markers, is given in
Figure 4H.
Tnfα Expression is Increased in Activated
Microglia in the Lesioned Nigrostriatal
System
In order to validate the expression of Tnfα analyzed on the
mRNA level and to determine the cell type responsible for the
increase in Tnfα expression, immunohistochemistry for Tnfα has
been performed on brain section ‘‘Materials and Methods’’ days
after 6-OHDA injections. Microglial Tnfα expression was
not detectable in the SN (Figures 5A–C) and in the CPu
(Figures 5G–I) on control sides. However, Figures 5D–F
demonstrates that distinct Tnfα immunoreactivity was observed
in activated microglia showing amoeboid morphologies on
lesioned sides as indicated by white arrows. In the lesioned
CPu, a similar staining pattern was observed. Again, activated
microglia with typical morphologic changes (white arrows)
showed positive Tnfα immunoreactivities (Figures 5J–L). In
both the lesioned areas, only activatedmicroglia as indicated with
white arrows expressed Tnfα, whereas ramified microglia (white
arrowhead) in close proximity to activated microglia showed no
Tnfα immunoreactivity. These data demonstrate that activated
microglia are the primary source of increased Tnfα expression in
the 6-OHDA-lesioned SN and CPu.
Tgfβ1 Expression is Increased in Striatal
Neurons and in Activated Microglia on the
Lesioned Side
After detection of increased Tgfβ1 expression in total tissue
samples from 6-OHDA-injected brains, we performed
immunohistochemistry staining for Tgfβ1 at 2 days after
6-OHDA injection to elucidate its cellular localization. As
FIGURE 5 | Microglial expression of Tnfα in the SN und the CPu after 6-OHDA injections. Two days after 6-OHDA-induced lesion no Tnfα expression was
observed in microglia in SN (A–C) and CPu (G–I). However, distinct Tnfα immunoreactivity could be detected on the lesioned side. Activated microglia (white arrows)
showed Tnfα expression in the SN (D–F) as well as in the CPu (J–L). No Tnfα signals were present in ramified non-activated microglia (white arrowheads) from the
SN (D–F) and the CPu (J–L) on the lesioned side. Representative images from three different animals are shown. Scale bars indicate 20 µm.
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shown in Figures 6A–C, Tgfβ1 was not expressed by microglia
(Iba1+ cells) in the SN on the control side, but by large-sized
midbrain neurons showing distinct Tgfβ1 immunoreactivity
(as indicated by asterisk). Figure 6G demonstrates that TH+
mDA neurons express Tgfβ1 (white arrows). A similar staining
pattern was observed in the CPu on the control side after
2 days (Figures 6I–K). Whereas microglia show no Tgfβ1
expression, striatal neurons displayed weak perinuclear and
cytoplasmic Tgfβ1 signals (Figures 6I,K, asterisk). Figures 6D–F
demonstrates that Tgfβ1 expression was observed in midbrain
neurons (asterisk) and activated microglia (white arrow) in
the SN on the lesioned side. Microglia with normal ramified
morphologies showed weak or no Tgfβ1 expression (white
arrowheads). TH+ mDA neurons further express Tgfβ1 on
the lesioned side (Figure 6H, white arrows). Interestingly, the
expression of Tgfβ1 was strongly increased in the CPu on the
lesioned side (Figures 6L–N). Robust Tgfβ1 immunoreactivity
was observed in striatal neurons (asterisks) and activated
microglia (white arrows) whereas ramified microglia did not
show expression of Tgfβ1. Using Map2 as neuronal maker,
increased expression of Tgfβ1 could be confirmed in striatal
neurons on the lesioned side (Figures 6O,P). Moreover, an
overall increase in immunoreactivity for Tgfβ1 was further
detected in the neuropil and extracellular space of the CPu on
the lesioned side 2 days after injection of 6-OHDA, indicating
secretion and extracellular storage of Tgfβ1. These data clearly
demonstrate that Tgfβ1 expression is increased in striatal
neurons and in activated microglia in the CPu on the lesioned
side 2 days after injection of 6-OHDA.
DISCUSSION
In the present study, we have demonstrated that microglia
quickly adopt a reactive state in the SN and CPu after injection
of 6-OHDA into the MFB. This microglial activation precedes
the substantial loss of TH+ neurons in the midbrain. The rapid
microglial response is followed by an astrocytic reaction, which
persists until 14 days after injection whereas microglial reactivity
decreased and morphological changes of microglia normalize
from 6 days onwards. The temporal microglia activation pattern
correlated with the expression of the pro-inflammatory markers
Tnfα and iNos, the latter of which being the essential enzyme for
NO production. Both factors have been shown to be involved in
driving the progression of neurodegeneration (Block et al., 2007).
Using immunohistochemistry, we were able to demonstrate
that activated microglia in the SN and CPu are the source
of Tnfα expression 2 days after injection of 6-OHDA into
the MFB. This microglia activation in the 6-OHDA model
of PD, which precedes degeneration of mDA neurons has
been demonstrated in several recent studies using different
6-OHDA injection approaches (Henry et al., 2009; Marinova-
Mutafchieva et al., 2009; Walsh et al., 2011; Stott and Barker,
2014), and underline the importance of microglial activation
in driving the progression of mDA neurodegeneration. Indeed,
inhibition of microglia reactions either by the anti-inflammatory
CX3CL1 (Pabon et al., 2011), or by application of doxycycline
(Lazzarini et al., 2013) resulted in reduced microglia-mediated
neuroinflammation and an increased survival of mDA neurons
after 6-OHDA injections. These results indicate the importance
of attenuating microglia activation in order to prevent excessive
neurodegeneration. Tgfβ1 is one of the endogenous factors that
have been shown to be involved in regulation of microglial
activation (Spittau et al., 2013; Butovsky et al., 2014). Tgfβ1
expression has been described to be low under normal conditions
and to increase in the lesioned CNS with microglia and/or
macrophages being the major sources (Lehrmann et al., 1998;
Vincze et al., 2010; Pál et al., 2012). Here, we describe that
Tgfβ1 was upregulated predominantly in the CPu, reaching a
peak after 2 days. Although we were able to show that neurons
predominantly express Tgfβ1 on control and lesioned sides,
activated microglia show increased Tgfβ1 expression in the
lesioned SN as well as in the lesioned CPu. The increased Tgfβ1
expression followed the expression peak of the pro-inflammatory
markers Tnfα and iNos, indicating that Tgfβ1 might be involved
in deactivation of microglia, which might subsequently result in
reduced microglia-mediated neurodegeneration. The molecular
mechanisms by which Tgfβ1 promotes its anti-inflammatory
effects on microglia are only partially understood. A possible
mechanism might be the Tgfβ1-dependent induction of NG2+
microglia as shown after LPS injection into the CNS (Xiang
et al., 2015). Interestingly, the induction of NG2+ cells has
also been reported after 6-OHDA injections (Kitamura et al.,
2010). NG2 is a member of the CSPG (chondroitin sulfate
proteoglycan) superfamily and has been shown to be a substantial
part of the glial scar (Tan et al., 2005). Moreover, recent
studies suggest that NG2 expression in microglia alters their
functional properties. Gao et al. (2010) demonstrated that
NG2 is involved in regulating the production and secretion
of inflammatory cytokines in activated microglia. In addition,
Smirkin et al. (2010) observed that NG2+ macrophages
promote neuron survival in ischemic lesions by increased
secretion of neuroprotective factors such as GDNF and IGF-
1. Release of neurotrophic factors, such as GDNF, has been
further reported in activated (Gfap+) astrocytes, extending the
functions of reactive astrocytes beyond their well-established
role during glial scar formation (Chen et al., 2005). The
observed astrocyte activation in the present study might also
be involved in the attempt to support neuron survival and
a functional recovery after 6-OHDA injections. The observed
temporal activation pattern suggests, that microglia might be
involved in driving astrocyte reactions, which has also been
proposed for several pathologies in the CNS (Liu et al., 2011).
However, the molecular mechanisms underlying microglia-
astroglia communication are not well understood and need to be
further elucidated.
The temporal and spatial expression patterns of Tgfβ1,
which we demonstrate in the present study, suggest that Tgfβ1
might be upregulated in order to decrease microglial activation
and further change their functional features. Interestingly,
we were able to detect increased expression of markers
for alternative (M2) microglial activation after injection of
6-OHDA into the MFB. Expression levels of Ym1 and Arg1
increased at early time-points (1 day, 2 days) after lesion,
with a second peak in the CPu after 14 days. Increased
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FIGURE 6 | Microglial expression of Tgfβ1 in the SN und the CPu after 6-OHDA injections. Two days after 6-OHDA-induced lesion weak microglial and
distinct neuronal Tgfβ1 expression (white asterisks) was observed in SN (A–C,G–G′′) and CPu (I–K,O,O′). However, increased Tgfβ1 immunoreactivity could be
detected on the lesioned side after 2 days (H–H′′). Activated microglia (white arrows) showed Tgfβ1 expression in the SN (D–F), whereas ramified microglia (white
arrowheads) showed no Tgfβ1 expression (D–F). A strong increase in Tgfβ1 immunoreactivity was observed in the lesioned CPu 2 days after 6-OHDA injections
(L–N). Next to activated microglia (white arrows) and neurons (white asterisks) the neuropil displayed prominent Tgfβ1 signals in the lesioned CPu (L,N).
Map2-positive striatal neurons displayed a weak Tgfβ1 immunoreactivity on control sides (O–O′′). After lesion, strong Tgfβ1 signals could be observed in
Map2-positive neurons in the CPu (P–P′′). Representative images from three different animals are shown. Scale bars indicate 20 µm (A–F,I–N) and 50 µm
(G,H,O,P).
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expression of Tgfβ1 preceded the upregulation of Ym1 and Arg1
after 14 days. As we have recently demonstrated, microglial
Tgfβ secretion and autocrine activation of Tgfβ signaling are
essential for IL-4-mediated upregulation of Ym1 and Arg1
(Zhou et al., 2012). It should be considered that Tgfβ1
might serve as an important endogenous factor that regulates
different microglia activation states, inhibitingM1 activation and
shifting microglia phenotypes towards M2 activation. However,
these Tgfβ1-mediated mechanisms, which have been shown
in vitro (Zhou et al., 2012; Spittau et al., 2013), must not
necessarily be relevant in vivo and at this stage remains
speculative.
It is noteworthy that the expression patterns of ActivinA
were similar to that of Tgfβ1. ActivinA has also been shown
to exert anti-inflammatory effects on activated microglia
(Ogawa et al., 2006; Sugama et al., 2007). Moreover, we
have demonstrated that the expression of Mfge8 was increased
after 2 days in the SN and to a lower extent in the CPu.
Although these increases in Mfge8 expression did not reach
significant differences, this secreted factor might be involved
in binding to apoptotic neurons to initiate a subsequent
uptake by microglia. Interestingly, we have previously shown
that Tgfβ1 increases the engulfment of apoptotic cells by
microglia, by increasing microglial Mfge8 expression (Spittau
et al., 2015).
The present study suggests that Tgfβ1 might be involved
in regulating and shaping microglia activation states in the
6-OHDA mouse model of PD. Current treatment strategies are
focussed on restoring the dopamine deficits by application of
L-3,4-dihydroxyphenylalanine (L-DOPA) and thereby reducing
motor symptoms of PD (Barbeau, 1969). However, L-DOPA
itself has been reported to induce glia reactions (Bortolanza et al.,
2014) and thus, is not an optimal treatment option. The anti-
inflammatory properties of Tgfβ1 and other immunoregulatory
factors should be considered during establishment and validation
of treatment paradigms in animal models of PD that aim to
reduce neurodegeneration. In the 6-OHDA model, the infusion
of GDNF and Tgfβ1 is more protective compared to the
treatment with GDNF alone (Gonzalez-Aparicio et al., 2010).
Similar results have been obtained in the MPTP mouse model of
PD (Schober et al., 2007). The combination of GDNF—as a very
potent neurotrophic factor—and Tgfβ1, as an anti-inflammatory
factor which reduces microglia-mediated neuroinflammation,
could be a powerful therapeutic option, especially, due the lack
of GDNF to inhibit the activation of mouse microglia, which do
not express essential signaling receptors (Ku et al., 2013; Zlotnik
and Spittau, 2014).
However, the molecular mechanisms of how Tgfβ1 affects
microglia activation states and functional properties are still only
partially understood. Moreover, excessive Tgfβ1 has detrimental
effects on CNS homeostasis and neuron survival (Wyss-Coray
et al., 1995, 1997) and therefore, detailed knowledge about
cellular expression, release, extracellular storage and activation
of Tgfβ1 is necessary before considering application of Tgfβ1
as a therapeutic agent. Furthermore, it remains to be elucidated
whether neuron- and/or microglia-derived Tgfβ1 is important to
silencemicroglia activation, thereby reducing neurodegeneration
in the 6-OHDA mouse model of PD. In conclusion, the data
presented in this study demonstrate that microglial activation
precedes the delayed astrocytic response and further reveal
the temporal and spatial expression patterns of inflammatory
and anti-inflammatory factors after an unilateral 6-OHDA
injection. The expression patterns of Tgfβ1 and ActivinA
suggest that these factors might be involved in regulating
microglial activation in this toxin-based model of PD. However,
further in vivo studies have to be performed in order to draw
conclusions about the mechanisms of Tgfβ1 and microglial
Tgfβ signaling in the regulation of microglia functions in PD
models.
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